NEFL and amyotrophic lateral sclerosis: These findings resembled those obtained in the II phase trial for ASOs in SOD1 ALS (Miller et al., 2020) and open new possible horizons for implementing blood NfL as a reliable and accessible marker of disease monitoring in clinical trials for neurodegenerative diseases.